Advantages

• Early Detection: Detect vascular changes linked to COPD and other lung diseases earlier.
• Precision and Speed: Automated AI analysis handles vascular complexity, reduces errors and saves time.
• Personalized Care: Enables clinicians to distinguish airway vs vascular phenotypes for tailored treatment strategies.

• Easy Integration: Designed to fit into existing imaging workflows and AI platforms for quick adoption.

   

Technology Description:

This breakthrough technology uses recently available artificial intelligence technology to analyze CT scans and render standardized measures of the pulmonary arterial tree size compared to lung volume. Such standardization is easier on the airways, and much harder on the vasculature, due to the prohibitively varied and complex vascular patterns. The result is a new biomarker, Arterial-to-Lung Ratio (ArtLR), which gives clinicians and researchers a consistent clear picture of the pulmonary arterial caliber and “arterial dysanapsis”. ArtLR helps identify early signs of diseases like COPD, supports better treatment decisions, and opens new doors for personalized care.

UIRF Case No. 2025-058

Stage of Development 

Version-1 of this biomarker was applied to a limited 110-subject SPIROMICS subset and unveiled interesting clinical associations. The Version-2 of this biomarker, with 5 major improvements will be ready by mid-January 2026, that will significantly streamline the pipeline, enhance stability and reproducibility, and reduce the computational burden, and will be used to analyze the larger more comprehensive 727-subjects of MESA-Lung cohort. The pipeline is projected to be additionally able to digest non-contrast TLC scans by May 2026.